Pfizer shelves Beqvez, a Spark Therapeutics developed product
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
The Pharma Letter2h
Pfizer’s Beqvez decision lays bare gene therapy challenges
US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...
pharmaphorum6h
Pfizer drops Beqvez, leaving gene therapy cupboard bare
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
GEN22h
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...